Robert Lufkin: Anti-Amyloid Drugs Fail Alzheimer’s Patients
Robert Lufkin, Advisor of Metabolic Health and Longevity Expert, shared post on LinkedIn:
“A Cochrane review of 17 trials and 20,342 patients concluded anti-amyloid drugs offer no clinically meaningful benefit for Alzheimer’s.
As a medical school professor, I have watched the amyloid hypothesis dominate Alzheimer’s research for 30 years.
Findings:
- 17 trials, 20,342 patients
- Effects on cognitive decline absent or trivial
- The drugs remove amyloid but raise brain bleeding and swelling risk
- Authors call for research on other mechanisms
Lead author Dr. Francesco Nonino:
‘These drugs make no meaningful difference to patients.’
This is the textbook story I called out in ‘Lies I Taught in Medical School.’
The amyloid hypothesis was elegant.
As a target, it was wrong.
Growing evidence points to Alzheimer’s as a metabolic disease – driven by insulin resistance, glucose hypometabolism, and mitochondrial dysfunction.
Metabolic dysfunction is the root cause of chronic disease.
Full breakdown coming on the Health Longevity Secrets podcast.
View Cochrane review.”
Stay updated on all scientific advances with Hemostasis Today.
-
Apr 30, 2026, 13:54Matthew D. Neal: A Major Step Forward in Trauma and Resuscitation Science
-
Apr 30, 2026, 13:35Day 2 of the EHC Youth Leadership Workshop 2026
-
Apr 30, 2026, 13:23The Gap Between Clinical Assessment and Patient Experience in VTE – RPTH Journal
-
Apr 30, 2026, 13:17Low Absolute Neutrophil Count Doesn’t Always Indicate Pathology – ASH Education
-
Apr 30, 2026, 13:01William Aird: When Inducers Make DOACs Fail
-
Apr 30, 2026, 12:56Abdul Muqtadir Abbasi: HIT Management – Avoid Platelet Transfusion
-
Apr 30, 2026, 12:45Chokri Ben Lamine: Methemoglobinemia in Hematology – Causes, Diagnosis, Antidote
-
Apr 30, 2026, 08:11Navya Sree: Breaking Down DVT From Theory to Practice
-
Apr 30, 2026, 06:06Shashank Joshi: The Emerging Role of Inflammatory Biomarkers in Acute CVS Thrombosis